Total Voting Rights and Capital

Summary by AI ^BETAClose X

Haleon plc announced that as of April 30, 2026, its total issued share capital comprises 8,891,932,595 ordinary shares, with 12,240,797 held in treasury. Consequently, the number of ordinary shares carrying voting rights is 8,879,691,798, which shareholders should use as the denominator for calculating any required notifications under the FCA's Disclosure Guidance and Transparency Rules.

Disclaimer*

Haleon PLC

01 May 2026

Icon Description automatically generated

Haleon plc: Total Voting Rights and Capital

01 May 2026: As at 30 April 2026 the total number of shares issued by Haleon plc ("Haleon" or the "Company") is 8,891,932,595 ordinary shares of £0.01 each, of which 12,240,797 are held as treasury shares.

Therefore, the number of ordinary shares with voting rights is 8,879,691,798 and this figure should be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Notifiable interests in Haleon may be sent to: company.secretary@haleon.com

Amanda Mellor

Company Secretary

About Haleon

Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion consumers and are recommended by health professionals around the world.

For more information, please visit www.haleon.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END